Evaluating the presence of SARS-CoV-2 RNA in the pleural fluid of patients undergoing pleural procedures without symptoms of COVID-19

E. Bedawi (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom), M. Fisher (Oxford, United Kingdom), Y. Zhao (Oxford, United Kingdom), V. George (Oxford, United Kingdom), A. Sundaralingam (Oxford, United Kingdom), X. Yao (Oxford, United Kingdom), A. Gondrand (Oxford, United Kingdom), M. Ellayeh (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), J. Thiboutot (Maryland, United States of America), C. Macrosty (North Carolina, United States of America), H. Lee (Maryland, United States of America), J. Akulian (North Carolina, United States of America), L. Yarmus (Maryland, United States of America), D. Feller-Kopman (Maryland, United States of America), T. Dong (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom)

Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease
Session: Accurate diagnosis and prediction of malignant pleural disease
Session type: E-poster
Number: 3104

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Bedawi (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom), M. Fisher (Oxford, United Kingdom), Y. Zhao (Oxford, United Kingdom), V. George (Oxford, United Kingdom), A. Sundaralingam (Oxford, United Kingdom), X. Yao (Oxford, United Kingdom), A. Gondrand (Oxford, United Kingdom), M. Ellayeh (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), J. Thiboutot (Maryland, United States of America), C. Macrosty (North Carolina, United States of America), H. Lee (Maryland, United States of America), J. Akulian (North Carolina, United States of America), L. Yarmus (Maryland, United States of America), D. Feller-Kopman (Maryland, United States of America), T. Dong (Oxford, United Kingdom), J. Wrightson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom). Evaluating the presence of SARS-CoV-2 RNA in the pleural fluid of patients undergoing pleural procedures without symptoms of COVID-19. 3104

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Mortality among patients with pleural effusion undergoing thoracentesis
Source: Eur Respir J 2015; 46: 495-502
Year: 2015



The necessity of examination of patients with pleural effusions by oncological programme
Source: Eur Respir J 2006; 28: Suppl. 50, 75s
Year: 2006

Evaluation of patients with pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 247s
Year: 2004

Impact of indwelling pleural catheter on quality of life in management of malignant pleural effusion in patients with advanced malignancies
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012



Blind pleural biopsy in the study of undiagnosed pleural effusion: results and complications
Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema
Year: 2020


Surgical problems with the malignant pleural space
Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis
Year: 2006


Complete and early drainage of exudates may be of clinical benefit in patients with loculated and/or free-flowing tuberculous pleurisy
Source: Breathe 2009; 5: 359
Year: 2009

Evaluation of concomitant pleural effusions in patients with lung cancers
Source: Eur Respir J 2007; 30: Suppl. 51, 668s
Year: 2007

Does blind percutaneous pleural biopsy have a role in the investigation of pleural effusion? A pooled analysis
Source: Annual Congress 2009 - Pleural diseases
Year: 2009


Are patients with malignant pleural effusions being referred appropriately for surgical intervention?
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Is it important to determine pleural fluid amylase in patients with malignant pleural effusions?
Source: Eur Respir J 2007; 30: Suppl. 51, 565s
Year: 2007

Correlation between pleural fluid and serum C-reactive protein in patients with pleural effusion due to different etiologies
Source: Virtual Congress 2020 – Interesting clinical problems for the respiratory physician
Year: 2020


Does pleural fluid sample size matter in the cytopathological assessment of unilateral pleural effusion?
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009

Diaphragm ultrasound examination before and after fluid drainage in patients with malignant pleural effusion
Source: Virtual Congress 2020 – Transthoracic and endobronchial ultrasound
Year: 2020


Predictors of successful pleurodesis for patients with malignant pleural effusions
Source: Eur Respir J 2004; 24: Suppl. 48, 493s
Year: 2004

Predictors of trapped lung in patients with malignant pleural effusions; comparison of pleural elastance and pleural fluid pH
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009


Impact of sarcopenia in long-term symptoms in patients with malignant pleural effusion.
Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease
Year: 2021


Can pleural biopsy histology in combination with pleural fluid adenosine deaminase be used for diagnoses of pleural TB?
Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis
Year: 2020


Critical issues in pleural fluid examinations: laboratory parameters, tumour markers and cytological methods
Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=110
Year: 2002

Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy
Source: Annual Congress 2011 - From outside to inside: access to the pleura
Year: 2011